What is Codexis?
Codexis, Inc., incorporated in 2002 and publicly traded as CDXS on NASDAQ, is a leader in enzyme engineering, headquartered in Redwood City, California. The company's core strength lies in its CodeEvolver technology, which facilitates the discovery, development, and enhancement of high-performance enzymes and proteins. These innovations are critical for improving manufacturing processes in therapeutics, molecular diagnostics, and pharmaceutical applications. Codexis's enzymes are engineered to boost production yields, reduce environmental impact through decreased energy consumption and waste, and enhance overall efficiency in the synthesis of small molecule pharmaceuticals and nucleic acid-based medicines. The company is also actively developing its ECO Synthesis platform, aimed at enabling scalable, enzymatic manufacturing of RNAi therapeutics. Codexis serves a diverse clientele across the pharmaceutical, biotherapeutics, food and beverage, and fine chemical industries, earning recognition such as the Presidential Green Chemistry Challenge Award for its sustainable manufacturing contributions.
How much funding has Codexis raised?
Codexis has raised a total of $160M across 4 funding rounds:
Series D
$37M
Stock Offering
$78M
Stock Offering
$5M
Debt
$40M
Series D (2006): $37M with participation from Maxygen, Pequot Ventures, Bio*One Capital, Chevron, and CMEA Ventures
Stock Issuance/Offering (2010): $78M, investors not publicly disclosed
Stock Issuance/Offering (2019): $5M supported by Casdin Capital
Debt (2024): $40M featuring Innovatus Capital Partners
Key Investors in Codexis
Innovatus Capital Partners
Innovatus Capital Partners specializes in long-term capital investments across various asset classes, focusing on opportunities created by market volatility and disruptions. The firm targets asset-based investments with strong cash flow, particularly in areas where value is misunderstood or mispriced.
Casdin Capital
Casdin Capital, LLC was founded in 2011 and brings a deep understanding, expertise and long-term perspective to financing the next generation of life science innovation. Specific only to the firm's diagnostics and molecular information portfolio, Casdin Capital has invested in many of the leading pioneers.
Chevron
Chevron Corporation, through its subsidiaries, engages in the integrated energy and chemicals operations in the United States and internationally. The company operates in two segments, Upstream and Downstream.
What's next for Codexis?
The recent major strategic investment positions Codexis for accelerated growth and further development of its innovative enzyme engineering solutions. With a focus on enhancing the production of pharmaceuticals and biotherapeutics, the company is poised to capitalize on the increasing demand for sustainable and efficient manufacturing processes. The ongoing development of its ECO Synthesis platform for RNAi therapeutics suggests a strategic push into emerging therapeutic modalities. This capital infusion will likely fuel research and development, expand manufacturing capabilities, and potentially broaden market reach, reinforcing Codexis's role as a key player in the advancement of green chemistry and biopharmaceutical production.
See full Codexis company page
